PD-L1 expression in gastroesophageal dysplastic lesions.
|
| Abstract |
Immunotherapy has been recently approved for gastric (GC) and gastroesophageal-junction adenocarcinomas (GEC), and PD-L1 immunohistochemical evaluation represents a promising predictive biomarker in this oncological setting. A series of 125 gastroesophageal dysplastic lesions (52 low-grade, 73 high-grade) was investigated for PD-L1 and DNA mismatch repair proteins status. PD-L1 was positive (combined positive score (CPS) ≥ 1) in 48 (31.0%) dysplastic lesions. A higher prevalence of PD-L1-positive cases was observed among esophageal specimens compared with gastric ones (p = 0.0003), in high-grade and adenocarcinoma samples in comparison with low-grade dysplasia (p < 0.0001), and in lesions with mismatch repair deficiency (p = 0.028). For 30 dysplastic samples, a synchronous matched invasive lesion (GC = 15, GEC = 15) was available and tested for PD-L1 expression; a discordant PD-L1 status was observed in 12/30 (40%) cases. A relatively high prevalence in PD-L1 positivity was observed among gastroesophageal dysplastic lesions and this should be taken into consideration for future therapeutic strategies based on this biomarker.
|
|---|---|
| Authors | Matteo Fassan, Stefano Brignola, Gianmaria Pennelli, Giulia Alberti, Valentina Angerilli, Alessandra Bressan, Antonio Pellino, Cristiano Lanza, Roberta Salmaso, Sara Lonardi, Salvatore Pucciarelli, Gaya Spolverato, Marco Scarpa, Stefano Realdon, Fabio Farinati, Claudio Luchini, Massimo Rugge, Fotios Loupakis |
| Journal | Virchows Archiv : an international journal of pathology (Virchows Arch) Vol. 477 Issue 1 Pg. 151-156 (Jul 2020) ISSN: 1432-2307 [Electronic] Germany |
| PMID | 31724072 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!